We and others have shown AML cells to express the aldo-keto reductase AKR1C3 [42], [43], [44] and our rationale for selecting MPA for redeployment as a potential antileukaemic drug is as an inhibitor of this enzyme [28]. The gene discussed is AKR1C3; the disease is acute myeloid leukemia.